Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
|Podcasts|November 11, 2019
DocTalk Podcast: Mental Health Stigma Panel
Author(s)Kevin Kunzmann
Listen in to the audio transcript of a policy- and public health-based discussion on mental health stigma from a panel of experts.
Advertisement
Hello everyone, and welcome to the DocTalk podcast. I’m Kevin Kunzmann, managing editor of MD Magazine®, and I’ll be your host for this special edition of DocTalk.
Normally, our show features a one-on-one conversation with a clinical expert. Each episode is typically 10-20 minutes, and focuses on one topic of healthcare at a time. But this week’s episode is going to be a little bit different.
About a month ago, I was asked to moderate a panel discussion on
Today’s episode is actually the live-recorded audio of that 45-minute discussion, featuring the excellent insights of our panel:
- Tammy Boyd, Chief Policy Officer of Black Women’s Health Imperative
- John Snook, Executive Director of the Treatment Advocacy Center
- Jeff Valliere, Director of Communications at FasterCures
We hope you enjoy the talk.
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Related to this article
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.
At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.
Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.
Advertisement
Advertisement